In The News

Latest News

3
min read

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Ofirnoflast ASH 2025 Presentations
Read More
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Latest News
Press Releases
Dec 7, 2025

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

Halia Therapeutics announced positive Phase 2a results at ASH 2025 showing that ofirnoflast achieved a 72% hematologic improvement rate with meaningful hemoglobin gains, broad activity across difficult-to-treat lower-risk MDS patients, and a favorable safety profile.
Read more
Press Releases
Nov 10, 2025

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Ofirnoflast ASH 2025 Presentations
Read more
Interviews/ Speaking/ Events
Press Releases
Oct 23, 2025

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromesg will go here

MDS Orphan Drug Designation for Ofirnoflast
Read more
Press Releases
Oct 6, 2025

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of Paul Jones as Chief Strategy Officer & GM, International Markets

Paul Jones as Chief Strategy Officer & GM International Markets
Read more
Interviews/ Speaking/ Events
Press Releases
Sep 4, 2025

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Halia presents at Morgan Stanley Conference 2025
Read more
Press Releases
Jul 16, 2025

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

HT-4253 completes Phase 1 NHV Clinical Trial
Read more
Press Releases
Jun 4, 2025

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

Halia Tx Completes MDS Phase 2 Enrollment
Read more
Interviews/ Speaking/ Events
Press Releases
May 28, 2025

Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi

CEO David Bearss to be Keynote speaker at Med Investment Forum 2025 in Abu Dhabi
Read more
Press Releases
Mar 11, 2025

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

Halia Tx awarded Novo Nordisk Golden Ticket
Read more